α-Iso-cubebene, a natural compound isolated from Schisandra chinensis fruit, has therapeutic benefit against polymicrobial sepsis

Biochemical and Biophysical Research Communications

Volumn 426, Issue 2, 2012, Pages 226-231

  Lee, Sung Kyun ^a,b   Kim, Sang Doo ^a   Lee, Ha Young ^a,b   Baek, Suk Hwan ^c   Ko, Min Jung ^d   Son, Beung Gu ^d   Park, Sejin ^d   Choi, Young Whan ^d   Bae, Yoe Sik ^a,b  

^a Sungkyunkwan University   (South Korea)

^b Dong A University   (South Korea)

^c Yeungnam University College of Medicine   (South Korea)

^d Pusan National University   (South Korea)

Author keywords

Iso cubebene; Inflammation; Organ failure; Sepsis

Indexed keywords

ALPHA ISO CUBEBENE; CYTOKINE; HYDROGEN PEROXIDE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; SCHISANDRA CHINENSIS EXTRACT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BACTERICIDAL ACTIVITY; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG ISOLATION; DRUG MECHANISM; IMMUNOCOMPETENT CELL; LEUKOCYTE; LYMPHOCYTE; MALE; MOUSE; NONHUMAN; PERITONEAL FLUID; PHAGOCYTOSIS; PNEUMONIA; PRIORITY JOURNAL; SCHISANDRA CHINENSIS; SEPSIS; SEPTIC SHOCK; SPLEEN CELL;

ANIMALS; ANTI-BACTERIAL AGENTS; APOPTOSIS; BACTERIA; BIOLOGICAL AGENTS; CYTOKINES; DISEASE MODELS, ANIMAL; LYMPHOCYTES; MALE; MICE; MICE, INBRED ICR; PNEUMONIA, BACTERIAL; SCHISANDRA; SEPSIS; SESQUITERPENES; SHOCK, SEPTIC;

MUS; SCHISANDRA CHINENSIS;

EID: 84866350562     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.08.070     Document Type: Article

References (20)

1. Cohen J. The immunopathogenesis of sepsis. Nature 2002, 420:885-891.
2. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit. Care Med. 2001, 29:1303-1310.
3. Aneja R., Fink M.P. Promising therapeutic agents for sepsis. Trends Microbiol. 2007, 15:31-37.
4. Döcke W.D., Randow F., Syrbe U., Krausch D., Asadullah K., Reinke P., et al. Monocyte deactivation in septic patients: restoration by IFN-gamma treatment. Nat. Med. 1997, 3:678-681.
5. Czermak B.J., Sarma V., Pierson C.L., Warner R.L., Huber-Lang M., Bless N.M., et al. Protective effects of C5a blockade in sepsis. Nat. Med. 1999, 5:788-792.
6. Calandra T., Echtenacher B., Roy D.L., Pugin J., Metz C.N., Hültner L., et al. Protection from septic shock by neutralization of macrophage migration inhibitory factor. Nat. Med. 2000, 6:164-170.
7. Hotchkiss R.S., Tinsley K.W., Swanson P.E., Schmieg R.E., Hui J.J., Chang K.C., et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J. Immunol. 2001, 166:6952-6963.
8. Wang S.D., Huang K.J., Lin Y.S., Lei H.Y. Sepsis-induced apoptosis of the thymocytes in mice. J. Immunol. 1994, 152:5014-5021.
9. Gogos C.A., Drosou E., Bassaris H.P., Skoutelis A. Pro- versus anti-inflammatory cytokine profile in patients with severe sepsis: a marker for prognosis and future therapeutic options. J. Infect. Dis. 2000, 181:176-180.
10. Reinhart K., Karzai W. Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit. Care Med. 2001, 29:S121-S125.
11. Ulloa L., Tracey K.J. The " cytokine profile" : a code for sepsis. Trends Mol. Med. 2005, 11:56-63.
12. Lee Y.J., Shim J.W., Lee Y.J., Park Y.H., Lee H.Y., Kim S.D., et al. Identification of a novel compound that stimulates intracellular calcium increase and CXCL8 production in human neutrophils from Schisandra chinensis. Biochem. Biophys. Res. Commun. 2009, 379:928-932.
13. Choi Y.W., Kim H.J., Park S.S., Chung J.H., Lee H.W., Oh S.O., et al. Inhibition of endothelial cell adhesion by the new anti-inflammatory agent alpha-iso-cubebene. Vasc. Pharmacol. 2009, 51:215-224.
14. Kim S.D., Lee H.Y., Shim J.W., Kim H.J., Yoo Y.H., Park J.S., et al. Activation of CXCR2 by extracellular matrix degradation product acetylated Pro-Gly-Pro has therapeutic effects against sepsis. Am. J. Respir. Crit. Care Med. 2011, 184:243-251.
15. Wang J., Silva J.P., Gustafsson C.M., Rustin P., Larsson N.G. Increased in vivo apoptosis in cells lacking mitochondrial DNA gene expression. Proc. Natl. Acad. Sci. USA 2001, 98:4038-4043.
16. Simard J.C., Simon M.M., Tessier P.A., Girard D. Damage-associated molecular pattern S100A9 increases bactericidal activity of human neutrophils by enhancing phagocytosis. J. Immunol. 2011, 186:3622-3631.
17. Weber G.F., Schlautkötter S., Kaiser-Moore S., Altmayr F., Holzmann B., Weighardt H. Inhibition of interleukin-22 attenuates bacterial load and organ failure during acute polymicrobial sepsis. Infect. Immun. 2007, 75:1690-1697.
18. Fisher C.J., Dhainaut J.F., Opal S.M., Pribble J.P., Balk R.A., Slotman G.J., et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994, 271:1836-1843.
19. Opal S.M., Fisher C.J., Dhainaut J.F., Vincent J.L., Brase R., Lowry S.F., et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit. Care Med. 1997, 25:1115-1124.
20. Remick D.G., Newcomb D.E., Bolgos G.L., Call D.R. Comparison of the mortality and inflammatory response of two models of sepsis: lipopolysaccharide vs. cecal ligation and puncture. Shock 2000, 13:110-116.